


WHO guidelines

# WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ



Cryotherapy

Large loop  
excision of the  
transformation  
zone

Cold knife  
conization



World Health  
Organization



WHO guidelines

**WHO guidelines for treatment  
of cervical intraepithelial  
neoplasia 2–3 and  
adenocarcinoma in situ:**

cryotherapy, large loop excision of the  
transformation zone, and cold knife conization

Catalogage à la source : Bibliothèque de l'OMS

WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization.

1.Cervical Intraepithelial Neoplasia – diagnosis. 2.Cervical Intraepithelial Neoplasia – therapy. 3.Cervical Intraepithelial Neoplasia – surgery. 4.Adenocarcinoma – diagnosis. 5.Adenocarcinoma – therapy. 6.Cryotherapy – utilization. 7.Conization – methods. 8.Uterine Cervical Neoplasms – prevention and control. 9.Guideline. I.World Health Organization.

ISBN 978 92 4 150677 9

(Classification NLM : WP 480)

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Switzerland

# Contents

Lists of participants	v
Process for managing declarations and conflicts of interest	ix
Acknowledgements	x
Acronyms and abbreviations	xi
Executive summary	xii
Summary treatment recommendations	xiii
1. Introduction	1
Target audience	1
Purpose	1
2. Methods	3
3. Recommendations	7
4. Research gaps and further considerations	11
5. Use of the guideline	12
Guideline dissemination	12
Guideline evaluation	12
Guideline update	13
References	14
<b>Annexes</b>	
Annex 1: Declarations of interest	16
Annex 2: Search strategies for evidence reviews	19
Annex 3: PRISMA flow diagram for inclusion and exclusion of studies for evidence reviews	20
Annex 4: List of references for studies included in evidence reviews	22

## **Supplemental material: GRADE evidence-to-recommendation tables and evidence profiles for each recommendation\***

\* Available online: [www.who.int/reproductivehealth/publications/cancers/treatment\\_CIN\\_2-3/en/index.html](http://www.who.int/reproductivehealth/publications/cancers/treatment_CIN_2-3/en/index.html)



## Lists of participants

### WHO Steering Group

#### **Nathalie Broutet (Lead)**

Reproductive Health and Research  
WHO Headquarters

#### **Jean-Marie Dangou**

Disease Prevention and Control  
WHO Regional Office for Africa

#### **Ibtihal Fadhil**

Noncommunicable Diseases  
WHO Regional Office for the Eastern  
Mediterranean

#### **Gunta Lazdane**

Sexual and Reproductive Health  
WHO Regional Office for Europe

#### **Silvana Luciani**

Cancer Prevention and Control  
WHO Regional Office for the Americas /  
Pan American Health Organization (PAHO)

#### **Arvind Mathur**

Making Pregnancy Safer and Reproductive  
Health  
WHO Regional Office for South-East Asia

#### **Amolo Okero**

Counselling and Testing, HIV/AIDS  
WHO Headquarters

#### **Somchai Peerapakorn**

Reproductive Health  
WHO Country Office – Thailand

#### **Andreas Ullrich**

Chronic Diseases Prevention and Management  
WHO Headquarters

#### **Cherian Varghese**

Noncommunicable Diseases and Health  
Promotion  
WHO Regional Office for the Western Pacific

#### **Adriana Velazquez**

Essential Medicines and Pharmaceutical  
Policies  
WHO Headquarters

#### **Marco Vitoria**

HIV Treatment and Care  
WHO Headquarters

#### **Lawrence Von Karsa**

Quality Assurance and Screening  
International Agency for Research on Cancer

### Guideline Development Group

#### **Marc Arbyn**

Unit of Cancer Epidemiology  
Scientific Institute of Public Health – Louis  
Pasteur  
Brussels, Belgium

#### **Paul D. Blumenthal**

Population Services International (PSI)  
Stanford University School of Medicine  
Department of Obstetrics and Gynecology  
Stanford, USA

#### **Joanna Cain (Chair)**

International Federation of Gynecology and  
Obstetrics (FIGO)  
London, United Kingdom

#### **Michael Chirenje**

Department Obstetrics and Gynaecology  
University of Zimbabwe Medical School  
Harare, Zimbabwe

#### **Lynette Denny**

Department Obstetrics and Gynaecology  
Groote Schuur Hospital  
Cape Town, South Africa

#### **Hugo De Vuyst**

Infections and Cancer Epidemiology  
International Agency for Research on Cancer  
Lyon, France

**Linda O'Neal Eckert**

Department of Global Health  
Gynecology Director  
Harborview Center for Sexual Assault and  
Traumatic Stress  
Seattle, USA

**Sara Forhan**

HIV Care and Treatment Branch  
Global AIDS Program  
Centers for Disease Control and Prevention (CDC)  
Atlanta, USA

**Eduardo Franco**

Division of Cancer Epidemiology  
McGill University  
Montreal QC, Canada

**Julia C. Gage**

Division of Cancer Epidemiology and Genetics  
National Cancer Institute  
Rockville, USA

**Francisco Garcia**

American Cancer Society  
Tucson, USA

**Rolando Herrero**

Prevention and Implementation Group  
International Agency for Research on Cancer  
Lyon, France

**José Jeronimo**

PATH

**Rengaswamy Sankaranarayanan**

Prevention and Implementation Group  
International Agency for Research on Cancer  
Lyon, France

**Vivien Tsu**

PATH  
Seattle, USA

**Methods Group**

Based at MacGRADE Collaborating Centre,  
McMaster University, Hamilton, Canada:  
systematic review team and GRADE  
methodologists

**Holger Schünemann (Lead Investigator)**

Department of Clinical Epidemiology and  
Biostatistics

**Reem A. Mustafa (Coordinator)**

Department of Clinical Epidemiology and  
Biostatistics

**Nancy Santesso (Coordinator)**

Department of Clinical Epidemiology and  
Biostatistics

**External Review Group****Irene Agurto**

Santiago, Chile

**Ahti Anttila**

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27670](https://www.yunbaogao.cn/report/index/report?reportId=5_27670)

